<DOC>
	<DOCNO>NCT01028495</DOCNO>
	<brief_summary>To assess safety efficacy combine therapy regimen RX-0201 plus Gemcitabine , subject metastatic pancreatic cancer .</brief_summary>
	<brief_title>A Safety Efficacy Study RX-0201 Plus Gemcitabine Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>Subjects enrol assess safety receive combination Gemcitabine plus RX-0201 . Gemcitabine administer prior RX-0201 intravenously 30-min iv infusion dose 1000 mg/m2 weekly 2 cycle ; 4-week cycle consist 3-week treatment phase follow 1 week rest phase . RX-0201 administer 250 mg/m2/day 24-hour continuous intravenous infusion 2 cycle ; 3-week cycle consist 2-week treatment phase follow 1 week rest phase . ( See schedule assessment ) Subjects enrolled evaluate efficacy receive combination Gemcitabine RX-0201 outline 4 cycle .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Provide write informed consent prior initiation study procedure . Are &gt; 18 year age Have metastatic pancreatic cancer . Have least 1 measurable lesion RECIST criterion . Have Karnofsky Performance Status &gt; 70 . Have least 6month life expectancy assess investigator . Premenopausal woman must surgically sterile agree use accept method birth control participate study 30 day follow last exposure study drug . Acceptable form birth control : hormonal contraceptive ( oral , injectable , transdermal implant ) , doublebarrier contraceptive ( condom diaphragm spermicide ) , intrauterine device ( IUD ) . Male subject need either surgically sterile agree use barrier method birth control describe study 30 day follow last exposure study drug . The subject 's agree upon method birth control discuss documented subject source document screen phase study . Are unwilling unable provide inform consent . Are unwilling unable comply requirement protocol . Have treat another investigational agent pancreatic cancer . Have follow screen laboratory value : Hemoglobin &lt; 8.0 grams/deciliter ( g/dL ) Absolute neutrophil count ( ANC ) &lt; 1500/microliter ( μL ) Platelet count &lt; 100,000/μL Serum creatinine &gt; 1.5 x institutional upper limit normal ( IULN ) creatinine . Serum bilirubin &gt; 1.5 X IULN Aspartate transaminase ( AST ) ( serum glutamic oxaloacetic transaminase , SGOT ) &gt; 2 x IULN ( &gt; 5 x IULN presence know liver metastasis ) Alanine transaminase ( ALT ) ( serum glutamate pyruvate transaminase , SGPT ) &gt; 2 x IULN ( &gt; 5 x IULN presence know liver metastasis ) Have prothrombin time &gt; 1.25 x IULN screen laboratory assessment . HCV HBsAg positive subject Have receive therapeutic dose either warfarin heparin within 21 day Day 1 ( first day dosing ; prophylactic use warfarin heparin ) maintain patency indwell IV catheters/lines allow Have history brain cancer ( primary metastatic ) . Have history active hematologic malignancy within past 2 year . Have underlying diagnosis disease state associate increase risk bleeding ( i.e. , coagulopathies , HIV ) . Have serious infection require intravenous antibiotic therapy screening . Females pregnant , lactating , positive serum pregnancy test screening period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>